CRP and cancer: If ln (CRP) were only a surrogate marker of FEV1 loss, the second adjustment of ln (CRP) would be expected to equalize the difference in ln (CRP) between patients with lung cancer and patients with other cancers, but this hypothesis was not confirmed.